Soligenix (SNGX) Competitors $2.92 +0.14 (+5.04%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.90 -0.02 (-0.86%) As of 09/12/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. FGEN, TPST, VRCA, LTRN, PEPG, NBRV, RNXT, ATHE, AADI, and ANVSShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include FibroGen (FGEN), Tempest Therapeutics (TPST), Verrica Pharmaceuticals (VRCA), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors FibroGen Tempest Therapeutics Verrica Pharmaceuticals Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio FibroGen (NASDAQ:FGEN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has more risk and volatility, FGEN or SNGX? FibroGen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Is FGEN or SNGX more profitable? Soligenix has a net margin of 0.00% compared to FibroGen's net margin of -3.86%. FibroGen's return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-3.86% N/A -27.34% Soligenix N/A -274.76%-129.20% Do insiders and institutionals hold more shares of FGEN or SNGX? 72.7% of FibroGen shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 3.1% of FibroGen shares are owned by insiders. Comparatively, 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better valuation & earnings, FGEN or SNGX? Soligenix has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.64-$47.58M-$0.38-31.66Soligenix$120K104.39-$8.27M-$3.80-0.77 Does the media favor FGEN or SNGX? In the previous week, FibroGen and FibroGen both had 2 articles in the media. Soligenix's average media sentiment score of 1.45 beat FibroGen's score of 0.68 indicating that Soligenix is being referred to more favorably in the news media. Company Overall Sentiment FibroGen Positive Soligenix Positive Do analysts rate FGEN or SNGX? FibroGen currently has a consensus price target of $43.00, suggesting a potential upside of 257.44%. Soligenix has a consensus price target of $6.00, suggesting a potential upside of 105.48%. Given FibroGen's higher possible upside, equities research analysts clearly believe FibroGen is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryFibroGen and Soligenix tied by winning 7 of the 14 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.91M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.7721.1774.5225.93Price / Sales104.39472.61547.62126.81Price / CashN/A46.6837.5660.44Price / Book1.789.6112.166.29Net Income-$8.27M-$53.29M$3.28B$270.77M7 Day Performance2.10%0.28%0.87%3.88%1 Month Performance19.18%5.73%4.96%4.88%1 Year Performance-19.11%10.52%60.75%26.01% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix2.7408 of 5 stars$2.92+5.0%$6.00+105.5%-14.9%$11.91M$120K-0.7720Short Interest ↓FGENFibroGen4.5114 of 5 stars$11.16-7.8%$43.00+285.3%+13.7%$48.93M$29.62M-29.37570News CoverageGap DownTPSTTempest Therapeutics2.4474 of 5 stars$10.85-1.3%$30.00+176.5%-40.7%$48.80MN/A-0.7420VRCAVerrica Pharmaceuticals4.0829 of 5 stars$5.06-1.0%$80.00+1,481.0%-75.5%$48.22M$7.57M-0.6140LTRNLantern Pharma2.5962 of 5 stars$4.06-5.8%$25.00+515.8%+1.1%$46.54MN/A-2.2820Positive NewsPEPGPepGen2.8238 of 5 stars$1.49+6.4%$7.67+414.5%-83.6%$45.92MN/A-0.5030Analyst ForecastGap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3401 of 5 stars$1.14-8.1%$7.50+557.9%+19.6%$45.44M$40K-3.006News CoverageShort Interest ↑Gap UpATHEAlterity Therapeutics2.4686 of 5 stars$5.17+2.0%$12.00+132.1%+287.3%$44.96MN/A0.0010High Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+13.6%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.5303 of 5 stars$2.34+2.1%$17.33+641.4%-70.6%$44.62MN/A-1.153 Related Companies and Tools Related Companies FibroGen Competitors Tempest Therapeutics Competitors Verrica Pharmaceuticals Competitors Lantern Pharma Competitors PepGen Competitors Nabriva Therapeutics Competitors RenovoRx Competitors Alterity Therapeutics Competitors Aadi Bioscience Competitors Annovis Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNGX Stock Alerts